ATTO Stock Forecast: Attovia Therapeutics, Inc. Price Predictions for 2026-2027
The 5 Wall Street analysts covering Attovia Therapeutics, Inc. hold a median 12-month price target of $45 — +97.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 0 of 100 as at 12 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
ATTO stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Attovia Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (44): Smaller than most of the companies we track.
Volatility (1): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
ATTO stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ATTO, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
The green dot is the last close — the median target sits +97.5% from it.
Of the 20 most recent actions, 1 moved their price target up and 6 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 31 Aug 2026 | Citigroup | Initiates | Buy | — |
| 31 Aug 2026 | Leerink Partners | Initiates | Outperform | — |
| 31 Aug 2026 | LifeSci Capital | Initiates | Outperform | — |
| 31 Aug 2026 | Morgan Stanley | Initiates | Overweight | — |
| 31 Aug 2026 | RBC Capital | Initiates | Outperform | — |
| 15 Aug 2022 | Barrington Research | Maintains | Outperform | $32 → $15 |
| 5 July 2022 | Goldman Sachs | Maintains | Neutral | $28 → $14 |
| 21 Sept 2021 | Goldman Sachs | Upgrade | Neutral | $11 → $30 |
| 25 Nov 2020 | Baird | Maintains | Outperform | — |
| 25 Nov 2020 | Bank of America | Maintains | Neutral | — |
| 25 Nov 2020 | Barrington Research | Initiates | Outperform | — |
| 25 Nov 2020 | Credit Suisse | Downgrade | Neutral | — |
| 25 Nov 2020 | Goldman Sachs | Downgrade | Sell | — |
| 25 Nov 2020 | Morgan Stanley | Downgrade | Equal-Weight | — |
| 30 Apr 2020 | Goldman Sachs | Downgrade | Sell | — |
| 5 June 2019 | Morgan Stanley | Downgrade | Equal-Weight | $8.00 → $3.00 |
| 8 Nov 2018 | Baird | Maintains | Outperform | $10 → $8.00 |
| 30 July 2018 | Baird | Maintains | Outperform | $12 → $10 |
| 3 Apr 2018 | Goldman Sachs | Initiates | Neutral | — |
| 21 Mar 2018 | Baird | Maintains | Outperform | $14 → $12 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ATTO appears on the weeks it earns a place.
ATTO analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Attovia Therapeutics, Inc. (ATTO) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −9.6×
- Price / sales
- 578.0×
- Price / book
- −6.7×
- EV / EBITDA
- −15.8×
Cheaper than 92% of US stocks
Cheaper than 2% of US stocks
Cheaper than 97% of US stocks
Cheaper than 88% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- −99.9%
- Gross margin
- —
- Operating margin
- −4845.1%
- Net margin
- 0.0%
Higher than 2% of US stocks
Higher than 3% of US stocks
Higher than 30% of US stocks
- Return on equity
- 56.7%
- Return on assets
- −36.7%
- Dividend yield
- —
Higher than 94% of US stocks
Higher than 11% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
Attovia Therapeutics, Inc. (ATTO) statistics: revenue, profit & scale
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Attovia Therapeutics, Inc. has a market value of $1.0B and an enterprise value of $1.2B.
Revenue in the twelve months to 30 June 2026: $450K.
Net income over the same four quarters: −$68.9M, a −15318.4% net margin.
Diluted earnings per share, trailing twelve months: $−2.37.
Trailing P/E: −9.6×; forward P/E: −9.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Attovia Therapeutics, Inc. employs 44 people — $10K of revenue per employee.
Data provided by Twelve Data
ATTO vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Attovia Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about ATTO stock
What is the ATTO stock price forecast for 2026-2027?
The 5 Wall Street analysts covering Attovia Therapeutics, Inc. have a median 12-month price target of $45, with estimates ranging from $30 to $52. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ATTO stock a buy right now?
Of the 5 analysts covering Attovia Therapeutics, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Attovia Therapeutics, Inc. 0 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ATTO?
As at 12 Sept 2026, Attovia Therapeutics, Inc. ranks 0 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (44 of 100).
Will ATTO stock go up?
No one can know that. What the data says: the median 12-month target from 5 analysts implies +97.5% from the last close, and Ticker Nerd's factor model ranks Attovia Therapeutics, Inc. 0 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ATTO stock forecast for 2030?
No analyst covering Attovia Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ATTO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $30 to $52 over the next 12 months.
What does Attovia Therapeutics, Inc. do?
Attovia Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing precision biologics for immune-mediated diseases.
About Attovia Therapeutics, Inc.
Attovia Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing precision biologics for immune-mediated diseases. The company’s core work centers on its ATTOBODY platform, which is designed to create multispecific protein therapies that target multiple disease pathways involved in inflammation and immune dysfunction. Its current pipeline includes candidates for dermatology conditions such as atopic dermatitis and chronic pruritus, as well as gastroenterology and inflammatory disorders, including inflammatory bowel disease. Attovia Therapeutics Inc. develops therapeutic programs aimed at areas with significant unmet medical need, using a platform-based approach intended to improve specificity and broaden treatment options across several disease areas. The company is based in San Carlos, California.
CEO Mr. Tao Fu M.B.A., M.S. · 44 employees · United States · https://www.attovia.com